Occlutech Holding AG, a leader in providing cutting-edge minimally invasive structural heart disease devices, is proud to announce the appointment of Dr. Morwan Choli as its new Vice President of Regulatory Affairs & Quality. Morwan will be joining the Executive Management Team and is sure to bring an impressive background of experience and knowledge to the table. Occlutech looks forward to utilizing his expertise as it continues to develop effective and safe treatments for patients.
Morwan is an accomplished professional with a wealth of experience in regulatory certification and management. His impressive educational background includes a diploma and Ph.D in Physics from Julius-Maximilian University Wuerzburg in Germany. He has also worked extensively in Magnetic Resonance Imaging with major research centers such as Forschungszentrum für Magnet-Resonanz-Bayern e.V (“MRB e.V”), Kopfklinik at University Hospital Heidelberg, and St. Judes Children’s Research Hospital in Memphis.
Morwan brings a wealth of experience to Occlutech in the field of Regulatory Affairs & Quality (RA&Q). Having previously worked with several Notified Bodies in the EU, as well as leading a medical device certification department in Germany and a medical device testing and certification division in Japan and Asia, Morwan is well-positioned to guide Occlutech in achieving their global RA&Q goals. His main focus will be to ensure that Occlutech obtains the necessary product approvals in the various regions, in order to meet local safety and performance requirements, as well as maintain these approvals.
We are thrilled to welcome Morwan to the Occlutech family and our Management Team! He brings with him a wealth of knowledge and experience in the certification processes of medical devices, and we look forward to having him on board as we continue to advance Occlutech’s product and market strategy. With Morwan’s ambition, we are confident that Occlutech will reach new heights.
On February 1, 2023, Occlutech proudly welcomed Dr. Morwan Choli to their Executive Management Team, joining Sabine Bois (CEO), Thomas Okke Frahm (VP IT), Sakarias Lindell (VP People & Culture), Luis Martin-Parras (VP Supply Chain & Manufacturing), Frank Dallmann (VP R&D), Lars Nordenskjöld (CFO), Jose de la Cortina (CCO), Mathias Bouzereau (VP Global Marketing & Business Development) and Jozef Bartunek (CMO). Oshri Budana, who was part of the Executive Management Team, has shifted his focus to Clinical Operations. With Dr. Choli’s addition, Occlutech’s Executive Management Team is now composed of 10 members, each committed to delivering the best possible results.
Occlutech is a pioneering company that strives to enhance the lives of people affected by heart conditions through its minimally invasive structural heart implants. With over 200 patents and 155,000 products sold to date, Occlutech has become a global leader in cardiac implant technology, offering solutions for congenital heart defects, stroke prevention, and heart failure. Since 2003, the Switzerland-based public limited liability company has employed around 290 people and has been selling its products in over 85 countries.